Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S5AL
|
|||
| Former ID |
DCL001040
|
|||
| Drug Name |
XTL-2125
|
|||
| Indication | Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Discontinued in Phase 1 | [1] | |
| Company |
XTL Biopharmaceutical
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mycobacterium RNA polymerase (MycB RNAP) | Target Info | Modulator | [2] |
| KEGG Pathway | Purine metabolism | |||
| Pyrimidine metabolism | ||||
| Metabolic pathways | ||||
| RNA polymerase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs for hepatitis C. Expert Opin Emerg Drugs. 2008 Mar;13(1):1-19. | |||
| REF 2 | DOI: 10.1111/j.1365-2036.2009.03927.x | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.